Xeltis Expands Leadership with New Appointment
Xeltis has announced the appointment of Luc Verhees as Vice President of Clinical Business Development. This strategic move enhances the leadership team at a pivotal moment for the company, particularly following the approval received for initiating the US pivotal study for aXess, its innovative restorative vascular access conduit.
Experience and Background of Luc Verhees
Luc Verhees brings with him over three decades of expertise in cardiovascular clinical research, business development, and medical affairs. His previous tenure at Xeltis as Senior Vice President of Global Clinical Affairs from 2018 to 2020 positions him as a well-versed addition to the team. This experience will play a critical role as Xeltis focuses on expanding its clinical initiatives, particularly in the lead-up to the US pivotal trial for the aXess conduit.
Comments from Leadership
Eliane Schutte, the Chief Executive Officer of Xeltis, expressed her enthusiasm through a statement: "With Luc's extensive knowledge and familiarity with the clinical trials landscape across various continents, he is a perfect fit as we progress towards commercializing aXess. His skills and track record will be instrumental in the success of our upcoming pivotal trial for aXess."
Luc Verhees' Vision
Luc himself shared his excitement about joining the Xeltis team, stating, "Xeltis' novel technology truly has the potential to transform patient outcomes. My passion for enhancing the standard of care in cardiovascular therapies aligns with the company's mission, and I look forward to contributing to the development of aXess and other clinical programs as we advance towards commercialization."
The Significance of aXess
Xeltis is making significant strides with aXess, which is designed to provide patients with a new, permanent vessel for hemodialysis vascular access. This restorative conduit significantly improves upon existing solutions by combining the reliability of a fistula with the speed of an AV graft. Thus, it enhances the patient experience while mitigating complications related to frequent reinterventions and infections commonly seen in patients undergoing renal care.
Clinical Trials and Future Outlook
The aXess design has proven effective, as indicated by a first-in-human trial which demonstrated a marked improvement in performance over traditional hemodialysis vascular access solutions. Currently, the pivotal trial for aXess is enrolling participants in multiple European countries, with a goal of reaching up to 110 patients. The IDE approval underscores Xeltis' position to not only improve patient care but also explore additional therapeutic applications for its pioneering implant technologies.
About Xeltis
Xeltis operates as a medtech company dedicated to the development of transformative implants that foster the natural creation of durable living vessels. The company aims to overcome existing limitations for people who rely on hemodialysis access grafts or cardiovascular replacements. Through its proprietary endogenous tissue restoration (ETR) platform, Xeltis has developed an innovative polymer implant that regenerates a patient’s own tissue, creating lasting vascular structures.
Innovation in Medical Technology
The flagship product currently under clinical investigation, known as aXess, aims to change the treatment landscape for hemodialysis patients. By merging safety, comfort, and efficiency, aXess presents an opportunity to improve the quality of life for patients in need of vascular access. With a crucial trial ongoing and more robust support from seasoned professionals like Luc Verhees, Xeltis appears poised for substantial growth and innovation in the medical field.
Frequently Asked Questions
Who is Luc Verhees?
Luc Verhees is the newly appointed Vice President of Clinical Business Development at Xeltis, with substantial experience in cardiovascular clinical research and affairs.
What is aXess?
aXess is a restorative conduit designed to create a new, permanent vessel for hemodialysis vascular access, enhancing patient care.
Why is aXess significant?
The aXess conduit improves the patient experience by combining the advantages of existing vascular access solutions while reducing complications.
What role does Luc Verhees play at Xeltis?
Verhees brings valuable expertise and leadership to Xeltis as it prepares to advance its clinical programs, particularly the pivotal trial for aXess.
How does Xeltis plan to progress?
Xeltis aims to leverage its innovative technologies and dedicated leadership to enhance clinical outcomes and commercialize its products like aXess effectively.
